

PHARMACY FACTS

Program Updates from Louisiana Medicaid

January 10, 2022

Provider Enrollment Portal

All providers who file claims with Louisiana Medicaid, including pharmacy providers, must enroll in the new Medicaid Provider Enrollment Portal **to continue getting reimbursed**.

Enrollment is mandated by CMS and applies to any provider that provides care to Medicaid members, which includes current managed care organization (MCO) only providers, Dental Benefits Program Manager (DBPM) providers, Coordinated System of Care (CSoc) providers, existing fee-for-service providers, and any new providers enrolling for the first time. All providers must login and submit an enrollment through the portal at www.lamedicaid.com by March 31, 2022.

To better support providers, **Louisiana Medicaid is conducting a provider enrollment drive, focused on pharmacy providers, from January 24 through February 21, 2022**. During this time, we will be working with your provider associations to encourage enrollment and provide you with additional resources.

More information is available at www.ldh.la.gov/medicaidproviderenrollment, including previously recorded webinars, a provider manual and frequently asked questions about the portal. If you have further questions about the portal or your www.lamedicaid.com account, please email LouisianaProvEnroll@gainwelltechnologies.com or call 833-641-2140, Monday – Friday between the hours of 8 a.m. and 5 p.m. CST.

Preferred Drug List (PDL) Update

The updated PDL that was implemented January 1, 2022 has been posted at <https://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>.

There are two new therapeutic classes added to the PDL including:

- Immunomodulators, Lupus.
- Ophthalmics, Cystinosis.

We have received questions about brand products that are preferred when the less-expensive generic version is non-preferred. For Medicaid to make a drug payable, the drug manufacturer is required by CMS to supply a rebate to Medicaid states. The rebate amount varies depending on the drug designation (brand or generic) and is adjusted due to the rate of price increase (CPI-U). Sometimes, the brand drug's net cost to the state is less than the generic version. LDH limits how many brand drugs are preferred over generics. The rebate program was designed to ensure Medicaid the best price, therefore saving taxpayer dollars.